private:atlantichc
|
553433
|
Nov 18th, 2019 12:00AM
|
Atlantic Healthcare plc
|
831
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 18th, 2019 03:46PM
|
Nov 18th, 2019 03:46PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 16th, 2019 12:00AM
|
Atlantic Healthcare plc
|
831
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 16th, 2019 03:57PM
|
Nov 16th, 2019 03:57PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 15th, 2019 12:00AM
|
Atlantic Healthcare plc
|
831
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 15th, 2019 12:39PM
|
Nov 15th, 2019 12:39PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 14th, 2019 12:00AM
|
Atlantic Healthcare plc
|
831
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 14th, 2019 05:55PM
|
Nov 14th, 2019 05:55PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 13th, 2019 12:00AM
|
Atlantic Healthcare plc
|
829
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 13th, 2019 01:07PM
|
Nov 13th, 2019 01:07PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 12th, 2019 12:00AM
|
Atlantic Healthcare plc
|
829
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 12th, 2019 02:49PM
|
Nov 12th, 2019 02:49PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 11th, 2019 12:00AM
|
Atlantic Healthcare plc
|
829
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 11th, 2019 02:47PM
|
Nov 11th, 2019 02:47PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 10th, 2019 12:00AM
|
Atlantic Healthcare plc
|
829
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 10th, 2019 05:54PM
|
Nov 10th, 2019 05:54PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 9th, 2019 12:00AM
|
Atlantic Healthcare plc
|
828
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 9th, 2019 05:21PM
|
Nov 9th, 2019 05:21PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|
private:atlantichc
|
553433
|
Nov 8th, 2019 12:00AM
|
Atlantic Healthcare plc
|
828
|
18.00
|
Open
|
Pharmaceuticals
|
Nov 8th, 2019 02:31PM
|
Nov 8th, 2019 02:31PM
|
Atlantic Healthcare is a specialist pharmaceutical company, focused on developing and commercializing gastrointestinal (GI) therapeutics which address unmet patient needs and rare diseases.
Our work is initially targeting the treatment of Inflammatory Bowel Disease (IBD), which has a debilitating effect on the lives of millions of people worldwide. In the worst cases, patients become house bound. This needs to change and we are playing our part by working with healthcare providers in pursuit of treatments that can improve the quality of life of patients with IBD.
We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatment for IBD and other GI diseases. Our lead program is a Phase 3 trial with Camligo™ (alicaforsen) enema for the treatment of orphan-designated pouchitis, a serious and rare form of IBD with no approved therapy and limited treatment options.
Our experienced Board of Directors and Leadership Team have deep knowledge of development, regulatory filings and commercialisation of products in North America and European markets. As a Company, we are working to develop and deepen the pipeline for alicaforsen with treatments for additional gastrointestinal indications.
|
Open
|
High growth, experienced international management, commercialisation, Gastrointestinal diseases, Inflammatory Bowel Disease, IBD, Crohn's disease, Ulcerative colitis, Pouchitis
|
Open
|
Atlantic House, 12 Rose and Crown Walk
|
Saffron Walden
|
Essex
|
GB
|
CB10 1JH
|
|
Atlantic Healthcare
|
|
|